VIR BIOTECHNOLOGY INC

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

12 Oct 2023 16:05:12 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023

11 Oct 2023 08:00:07 By Nasdaq GlobeNewswire

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

05 Oct 2023 16:30:36 By Nasdaq GlobeNewswire

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

03 Oct 2023 07:59:34 By Nasdaq GlobeNewswire

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

20 Sep 2023 08:00:12 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

29 Aug 2023 16:30:12 By Nasdaq GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

03 Aug 2023 16:05:56 By Nasdaq GlobeNewswire

Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023

26 Jul 2023 16:05:09 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

20 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

29 Jun 2023 09:00:23 By Nasdaq GlobeNewswire

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

24 Jun 2023 05:30:27 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

07 Jun 2023 02:13:21 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

05 Jun 2023 16:05:11 By Nasdaq GlobeNewswire

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

17 May 2023 16:05:46 By Nasdaq GlobeNewswire

Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

15 May 2023 08:00:01 By Nasdaq GlobeNewswire

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

11 May 2023 08:30:29 By Nasdaq GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results

04 May 2023 16:05:43 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference

03 May 2023 16:05:37 By Nasdaq GlobeNewswire

Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

02 May 2023 09:00:55 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 16:05:18 By Nasdaq GlobeNewswire